Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August?

A year ago, the Alzheimer’s drug development scene exploded with excitement after the approval of Biogen and Eisai’s Aduhelm. Major pharmaceutical companies were in a moment where they saw the possibility of their experimental therapies getting approved and gaining a foothold in the market.

But now, executives from two of the three major players that have reported second quarter earnings so far—Roche and Biogen—seem to be tempering expectations for success.

The third leading Alzheimer’s developer, Eli Lilly, will report its second quarter updates on Aug. 4, leaving an important question on how the Alzheimer's drug development field will shape up this year.